LanZhou Foci Pharmaceutical Co.,Ltd.

SZSE:002644 Lagerbericht

Marktkapitalisierung: CN¥3.9b

LanZhou Foci PharmaceuticalLtd Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 1/6

LanZhou Foci PharmaceuticalLtd's earnings have been declining at an average annual rate of -6%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 14.2% per year. LanZhou Foci PharmaceuticalLtd's return on equity is 2.7%, and it has net margins of 4.7%.

Wichtige Informationen

-6.0%

Wachstumsrate der Gewinne

-6.0%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie10.9%
Wachstumsrate der Einnahmen14.2%
Eigenkapitalrendite2.7%
Netto-Marge4.7%
Letzte Ertragsaktualisierung30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Why LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 01
Why LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Shaky Earnings Are Just The Beginning Of Its Problems

LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Weak Earnings May Only Reveal A Part Of The Whole Picture

Apr 17
LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Weak Earnings May Only Reveal A Part Of The Whole Picture

Recent updates

Why LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 01
Why LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Shaky Earnings Are Just The Beginning Of Its Problems

These 4 Measures Indicate That LanZhou Foci PharmaceuticalLtd (SZSE:002644) Is Using Debt Reasonably Well

Aug 07
These 4 Measures Indicate That LanZhou Foci PharmaceuticalLtd (SZSE:002644) Is Using Debt Reasonably Well

LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Weak Earnings May Only Reveal A Part Of The Whole Picture

Apr 17
LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Weak Earnings May Only Reveal A Part Of The Whole Picture

LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

Mar 13
LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

Mar 13
LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

Aufschlüsselung der Einnahmen und Ausgaben

Wie LanZhou Foci PharmaceuticalLtd Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

SZSE:002644 Einnahmen, Ausgaben und Erträge (CNY Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Sep 249894624231
30 Jun 241,0364623531
31 Mar 241,1196225132
31 Dec 231,1636725231
30 Sep 231,22711624430
30 Jun 231,20611523830
31 Mar 231,12411121326
01 Jan 231,04210920024
30 Sep 228527514223
30 Jun 228939716121
31 Mar 228779214420
01 Jan 228189314119
30 Sep 218307115415
30 Jun 217265812815
31 Mar 2170811814012
31 Dec 2066810812415
30 Sep 2066411016219
30 Jun 2064612815920
31 Mar 206117515523
31 Dec 196297515621
30 Sep 196079012419
30 Jun 195837611819
31 Mar 195586510619
31 Dec 185457410120
30 Sep 185817910421
30 Jun 18552828126
31 Mar 18543838022
31 Dec 17501747917
30 Sep 17420666610
30 Jun 1740565760
31 Mar 1737765730
31 Dec 1636361690
30 Sep 1633757610
30 Jun 1634554610
31 Mar 1633946580
31 Dec 1532843570
30 Sep 1533440580
30 Jun 1534638580
31 Mar 1537135570
31 Dec 1439935600
30 Sep 1438434560
30 Jun 1435833600
31 Mar 1431931630
31 Dec 1329231670

Qualität der Erträge: 002644 has high quality earnings.

Wachsende Gewinnspanne: 002644's current net profit margins (4.7%) are lower than last year (9.4%).


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: 002644's earnings have declined by 6% per year over the past 5 years.

Beschleunigtes Wachstum: 002644's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Erträge im Vergleich zur Industrie: 002644 had negative earnings growth (-60.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).


Eigenkapitalrendite

Hohe Eigenkapitalrendite: 002644's Return on Equity (2.7%) is considered low.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren